Peptides / Longevity and mitochondria

Synthetic analog · 3 amino acids · 375.4 Da

Ovagen (EDL)

Ovagen is a short synthetic peptide (Glu-Asp-Leu) from the Khavinson bioregulator family, sold in Russia as a dietary supplement. Its studies are in animals and lab cells, on the kidneys, markers of aging and oxidative stress. PepBank shows 14 results on Ovagen from animal and lab studies. No study in people has reported results yet. Data as of 2026-10-30.

Also known as EDL, Glu-Asp-Leu, Ovagen, Ovagen peptide

3 amino acids, from first to lastEDL

Evidence level: Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Results in people

0% of 14 results

Results in animals

57% of 14 results

Results in lab cells

43% of 14 results

From computer models

0% of 14 results

Overview

Ovagen (EDL) at a glance

What it is	Synthetic analog, 3 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	5 studies with results. 4 of them gave Ovagen, with 14 results. 8 in animals6 in lab cells
Clinical trials	None registered
Community use	Community interest in liver and digestive health

The science

What is Ovagen?

Synthetic Glu-Asp-Leu peptide from the Khavinson bioregulator family.

Amino acids in one chain

Ovagen (EDL) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 3 amino acidsFrom the first amino acid to the last

−E1−DL

Darker means more water-repelling+ and − show charge in the body

Structure

Ovagen (EDL) is a synthetic analog of 3 amino acids, with no ring, no changed amino acids.

Formula

C₁₅H₂₅N₃O₈

Molecular weight

375.4 g/mol

Development

Highest phase: no known clinical development.

Identifiers

PubChem 444128

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Glu-Asp-Leu-OH

InChIKey
JVSBYEDSSRZQGV-GUBZILKMSA-N

SMILES
CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Ovagen studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Kidneys and bladder

6 results · 6 animal

In rats with experimental kidney injury, EDL prevented low urine output. Bulletin of experimental biology and medicine, 2017

Cells, genes and aging

7 results · 2 animal · 5 lab

In rats with experimental kidney injury, EDL prevented a critical decrease in antioxidant enzyme activities. Bulletin of experimental biology and medicine, 2017

Key Ovagen studies

Studies in people come first, then studies in animals and in the lab.

Animals
Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis
Zamorskii et al. 2017 · Bulletin of experimental biology and medicine · cited by 4
7 results
Animals
[The influence of peptides on the morphofunctional state of old rats kidneys.]
Zamorskii et al. 2018 · Advances in gerontology = Uspekhi gerontologii · cited by 1
1 result
Lab cells
Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging
Khavinson et al. 2014 · Bulletin of experimental biology and medicine · cited by 6
1 result
Lab cells
[Tripeptides slow down aging process in renal cell culture]
Khavinson et al. 2014 · Advances in gerontology = Uspekhi gerontologii · cited by 0
5 results

All 5 Ovagen (EDL) studies

Ovagen clinical trials

ClinicalTrials.gov lists no trial of Ovagen. A trial under another name may exist.

Status and safety

Is Ovagen approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Ovagen side effects and safety

PepBank has no safety result from studies of Ovagen yet. That does not mean Ovagen is safe.

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The guide describes liver and digestive health interest. It reports a use pattern, without proof of safety or benefit.

Reported routines and cautions

What people use it for

Community interest in liver and digestive healthS1

Reported regimens

Regimens that community sources report for Ovagen. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community interest in liver and digestive health	subcutaneous injection	1 to 2 mg per dose	once daily	10 to 30 days	Single non-vendor guide. The underlying community reports were not independently verified.	S1

Community sources

S1Ovagen dosage, protocols and mixing | Vial Guide (opens in a new tab)vialguide.com

Gaps

This is one secondary guide. It does not identify the underlying community reports. Other regimens exist in the guide. No official medicine label was established. Product purity and actual use were not independently tested.

Questions and more

Ask a question about Ovagen

The answer links to every study it uses.

What does the evidence say about Ovagen?Is Ovagen tested in people?Compare with NMN (nicotinamide mononucleotide)Compare with Elamipretide (SS-31)

Sources

Database: PepBank data for Ovagen (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Ovagen

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Ovagen (EDL)

Also known as EDL, Glu-Asp-Leu, Ovagen, Ovagen peptide

What it is

Synthetic analog, 3 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

5 studies with results. 4 of them gave Ovagen, with 14 results.
8 in animals6 in lab cells

Clinical trials

None registered

Community use

Community interest in liver and digestive health

Context

Route

Amount

How often

How long

Agreement

Sources

Community interest in liver and digestive health

subcutaneous injection

1 to 2 mg per dose

once daily

10 to 30 days

Single non-vendor guide. The underlying community reports were not independently verified.

Ovagen (EDL)

Ovagen (EDL) at a glance

What is Ovagen?

Ovagen (EDL) structure and chemistry